404

We’re sorry, but the page you were looking for doesn’t exist.

[st_search style=”element” align=”center” placeholder=”Enter keywords” width=”40%”][/st_search]

Partners4AccessFollow

Coming up at #WODCUSA is a panel on “Articulating the value of curative therapies for pricing and reimbursement” which will be moderated by Akshay Kumar, Partner here at #P4A. The panel will live so we encourage you to join at 09:50 ET(14:50 UK time)and any questions you may have

Reply on Twitter 1298980548166037504 Retweet on Twitter 12989805481660375041 Like on Twitter 12989805481660375041 Twitter 1298980548166037504

Partners4Access @Partners4A·

26 Aug

Evert Van Lente,#AOK shared his ideal future for OMP legislation.Whilst we at #P4A are fully aligned with the vision for a sustainable #raredisease world,there needs to be a balance struck between payer affordability,patientaccess and a fair return on investment for manufacturers

Reply on Twitter 1298622547844567043 Retweet on Twitter 1298622547844567043 Like on Twitter 1298622547844567043 Twitter 1298622547844567043

Partners4Access @Partners4A·

26 Aug

Make sure to check out our very own Sophie Schmitz’s panel on Successfully navigating a new era: outlooks on future access to treatments, cures and clinical trials for rare disease patients at Wednesday, August 26, 2020 4:05 PM (UK time). #wodcusa #WODC #Raredisease

Reply on Twitter 1298593539874607104 Retweet on Twitter 12985935398746071041 Like on Twitter 12985935398746071041 Twitter 1298593539874607104

Partners4Access @Partners4A·

4 Aug

France to place restrictions on the Nominative ATU. In our blog we explore the reasons behind this and the implications for industry who previously sought this route as an early revenue opportunity.
#France #ATU #MarketAccess

Reply on Twitter 1290688437666877440 Retweet on Twitter 1290688437666877440 Like on Twitter 1290688437666877440 Twitter 1290688437666877440